APA
Jitschin R., Saul D., Braun M., Tohumeken S., Völkl S., Kischel R., Lutteropp M., Dos Santos C., Mackensen A. & Mougiakakos D. (20191025). CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. : Journal for immunotherapy of cancer.
Chicago
Jitschin Regina, Saul Domenica, Braun Martina, Tohumeken Sehmus, Völkl Simon, Kischel Roman, Lutteropp Michael, Dos Santos Cedric, Mackensen Andreas and Mougiakakos Dimitrios. 20191025. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. : Journal for immunotherapy of cancer.
Harvard
Jitschin R., Saul D., Braun M., Tohumeken S., Völkl S., Kischel R., Lutteropp M., Dos Santos C., Mackensen A. and Mougiakakos D. (20191025). CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. : Journal for immunotherapy of cancer.
MLA
Jitschin Regina, Saul Domenica, Braun Martina, Tohumeken Sehmus, Völkl Simon, Kischel Roman, Lutteropp Michael, Dos Santos Cedric, Mackensen Andreas and Mougiakakos Dimitrios. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. : Journal for immunotherapy of cancer. 20191025.